| 摘要 |
The use of 4-[2-[p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-pro penyl]phenoxy]ethyl]-morpholine, simultaneously, separately or sequentially in combination with a synergistically effective amount of cyclophosphamide in cancer prophylaxis or therapy for mammary tumors in mammals is described. |
